In the search for a preventative treatment of skin cancers, including melanoma, it is imperative to understand and treat DNA damage caused by ultraviolet (UV) radiation. Following the treatment of a ...

European regulators to evaluate new drug’s safety and efficacy for ‘orphan’ disease erythropoietic protoporphyria (EPP) SCENESSE®, which received an orphan drug designation for EPP in 2008, will be ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Clinuvel Pharmaceuticals (ASX:CUV) has moved back into focus after the European ...

Clinuvel Pharmaceuticals' shares rose after the US FDA removed a postmarketing requirement for a cardiac safety study on its lead therapy, SCENESSE. The decision follows a review of long-term clinical ...

FDA awards Fast Track Designation¹ to expedite review of SCENESSE® in EPP NDA filing allowed on a rolling basis FDA hosting a Scientific Workshop² on EPP to learn more about disease and drug treatment ...

It wasn’t so long ago that Australian drugmaker Clinuvel spurned a buyout attempt by Retrophin and its wayward then-CEO Martin Shkreli, preferring to soldier on alone with its sole drug candidate. Now ...

Health Canada’s Health Products and Food Branch (HPFB) reviews and approves medications for use in Canada, assessing the safety and efficacy of the products in the proposed indication, as well as the ...

The UK's cost-effectiveness agency NICE has delivered its final verdict on Clinuvel's Scenesse, a treatment for a rare skin disorder that causes extreme sensitivity to light, and it isn't good news ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

Note to editors: CLINUVEL is releasing in-depth infographics and a video explaining the mechanisms of action in XP and the overall DNA repair process. For updates, follow:Twitter | Facebook | ...